Atherosclerosis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 258 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atherosclerosis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H2 2015', provides an overview of the Atherosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Atherosclerosis Overview 10
Therapeutics Development 11
Pipeline Products for Atherosclerosis - Overview 11
Pipeline Products for Atherosclerosis - Comparative Analysis 12
Atherosclerosis - Therapeutics under Development by Companies 13
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 16
Atherosclerosis - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Atherosclerosis - Products under Development by Companies 21
Atherosclerosis - Products under Investigation by Universities/Institutes 24
Atherosclerosis - Companies Involved in Therapeutics Development 26
Ache Laboratorios Farmaceuticos S/A 26
advanceCor GmbH 27
AFFiRiS AG 28
Arisaph Pharmaceuticals, Inc. 29
Artery Therapeutics, Inc. 30
AstraZeneca Plc 31
Athera Biotechnologies AB 32
AtheroNova Inc. 33
Bayer AG 34
Campus Technologies Freiburg GmbH 35
Cardax Pharmaceuticals, Inc. 36
Cerenis Therapeutics Holding SA 37
ChemoCentryx, Inc. 38
CohBar, Inc. 39
Daiichi Sankyo Company, Limited 40
DoNatur GmbH 41
Dybly AG 42
Exicure, Inc. 43
F. Hoffmann-La Roche Ltd. 44
GenKyoTex S.A. 45
Gilead Sciences, Inc. 46
Jenrin Discovery, Inc. 47
Johnson & Johnson 48
KineMed, Inc. 49
Kowa Company, Ltd. 50
La Jolla Pharmaceutical Company 51
Lead Discovery Center GmbH 52
Merck & Co., Inc. 53
MI.TO. Technology S.r.L. 54
Omeros Corporation 55
OPKO Health, Inc. 56
Otsuka Holdings Co., Ltd. 57
Provid Pharmaceuticals, Inc. 58
Resverlogix Corp. 59
The Medicines Company 60
Therapix Biosciences Ltd 61
Tolerys SA 62
Vascular Biogenics Ltd. 63
Vericel Corporation 64
Virocan Therapeutics Private Limited 65
Vitae Pharmaceuticals, Inc. 66
Atherosclerosis - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 73
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
6860766 - Drug Profile 80
AEM-28 - Drug Profile 81
AG-01 - Drug Profile 82
AHRO-001 - Drug Profile 83
AHRO-002 - Drug Profile 85
AHRO-003 - Drug Profile 86
AM-0010 - Drug Profile 87
AmVidcm-009 - Drug Profile 88
anacetrapib - Drug Profile 89
Annexin A-5 - Drug Profile 91
apabetalone - Drug Profile 93
ARI-1778 - Drug Profile 96
Artpep-2 - Drug Profile 97
ATH-03 - Drug Profile 98
ATH-04 - Drug Profile 99
ATH-05 - Drug Profile 100
ATH-06 - Drug Profile 101
AZ-876 - Drug Profile 102
BAY-606583 - Drug Profile 103
BSN-272 - Drug Profile 104
CCX-771 - Drug Profile 105
CDX-085 - Drug Profile 106
Cell Therapy for Atherosclerosis - Drug Profile 108
Cellular Immunotherapy for Atherosclerosis - Drug Profile 109
CER-209 - Drug Profile 110
CM-7 - Drug Profile 111
COR-2 - Drug Profile 112
D-4F - Drug Profile 113
DIAS-2 - Drug Profile 114
Drug for Atherosclerosis - Drug Profile 115
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 116
Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 117
DYB-186 - Drug Profile 118
EP-80317 - Drug Profile 119
FX-5A - Drug Profile 120
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 121
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 122
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 123
GKT-831 - Drug Profile 124
GYY-4137 - Drug Profile 125
Humanin - Drug Profile 127
INV-88 - Drug Profile 129
ISIS-APOARx - Drug Profile 130
ITP-01 - Drug Profile 131
ixmyelocel-T - Drug Profile 132
JD-2000 Series - Drug Profile 135
JD-5000 Series - Drug Profile 136
JD-6000 Series - Drug Profile 137
K-312 - Drug Profile 138
K-877 - Drug Profile 139
KM-011 - Drug Profile 141
KRP-206 - Drug Profile 142
leucine + niacin - Drug Profile 143
LJPC-6417 - Drug Profile 144
LPC-01 - Drug Profile 145
MCS-18 - Drug Profile 146
MDCO-216 - Drug Profile 148
melittin - Drug Profile 150
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 151
Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile 153
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 154
Oligonucleotides to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile 155
P-16 - Drug Profile 157
PC-mAb - Drug Profile 158
Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile 160
PR-15 - Drug Profile 161
Protein for Cardiovascular Diseases - Drug Profile 163
Px-102 - Drug Profile 164
Recombinant Protein for Atherosclerosis - Drug Profile 166
Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile 167
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 169
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile 170
RO-6836191 - Drug Profile 171
rPAI-123 - Drug Profile 172
Small Molecule for Atherosclerosis - Drug Profile 173
Small Molecule for Atherosclerosis - Drug Profile 174
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 175
Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile 176
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 177
Small Molecule to Target GPR132 for Atherosclerosis - Drug Profile 178
Small Molecule to Target GPR176 for Atherosclerosis - Drug Profile 179
Small Molecules for Atherosclerosis - Drug Profile 180
Small Molecules for Inflammatory Diseases - Drug Profile 181
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 182
Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile 184
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 185
Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile 186
SPX-7233801 - Drug Profile 187
SR-9009 - Drug Profile 188
Stem Cell Therapy for Atherosclerosis - Drug Profile 189
Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile 190
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 192
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 194
Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 195
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 196
Vaccine for Atherosclerosis - Drug Profile 198
Vaccine for Atherosclerosis - Drug Profile 199
Vaccine for Atherosclerosis - Drug Profile 200
VB-201 - Drug Profile 201
VTP-4 - Drug Profile 203
Atherosclerosis - Recent Pipeline Updates 204
Atherosclerosis - Dormant Projects 231
Atherosclerosis - Discontinued Products 236
Atherosclerosis - Product Development Milestones 238
Featured News & Press Releases 238
Appendix 250
Methodology 250
Coverage 250
Secondary Research 250
Primary Research 250
Expert Panel Validation 250
Contact Us 250
Disclaimer 251

List of Tables

Number of Products under Development for Atherosclerosis, H2 2015 18
Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 21
Number of Products under Development by Companies, H2 2015 (Contd..1) 22
Number of Products under Investigation by Universities/Institutes, H2 2015 24
Comparative Analysis by Late Stage Development, H2 2015 25
Comparative Analysis by Clinical Stage Development, H2 2015 26
Comparative Analysis by Early Stage Development, H2 2015 27
Products under Development by Companies, H2 2015 28
Products under Development by Companies, H2 2015 (Contd..1) 29
Products under Development by Companies, H2 2015 (Contd..2) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 32
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 33
Atherosclerosis - Pipeline by advanceCor GmbH, H2 2015 34
Atherosclerosis - Pipeline by AFFiRiS AG, H2 2015 35
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 36
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2015 37
Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2015 38
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2015 39
Atherosclerosis - Pipeline by AtheroNova Inc., H2 2015 40
Atherosclerosis - Pipeline by Bayer AG, H2 2015 41
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H2 2015 42
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 43
Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 44
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2015 45
Atherosclerosis - Pipeline by CohBar, Inc., H2 2015 46
Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 47
Atherosclerosis - Pipeline by DoNatur GmbH, H2 2015 48
Atherosclerosis - Pipeline by Dybly AG, H2 2015 49
Atherosclerosis - Pipeline by Exicure, Inc., H2 2015 50
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 51
Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2015 52
Atherosclerosis - Pipeline by Gilead Sciences, Inc., H2 2015 53
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H2 2015 54
Atherosclerosis - Pipeline by Johnson & Johnson, H2 2015 55
Atherosclerosis - Pipeline by KineMed, Inc., H2 2015 56
Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2015 57
Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H2 2015 58
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2015 59
Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2015 60
Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H2 2015 61
Atherosclerosis - Pipeline by Omeros Corporation, H2 2015 62
Atherosclerosis - Pipeline by OPKO Health, Inc., H2 2015 63
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 64
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H2 2015 65
Atherosclerosis - Pipeline by Resverlogix Corp., H2 2015 66
Atherosclerosis - Pipeline by The Medicines Company, H2 2015 67
Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H2 2015 68
Atherosclerosis - Pipeline by Tolerys SA, H2 2015 69
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2015 70
Atherosclerosis - Pipeline by Vericel Corporation, H2 2015 71
Atherosclerosis - Pipeline by Virocan Therapeutics Private Limited, H2 2015 72
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 73
Assessment by Monotherapy Products, H2 2015 74
Assessment by Combination Products, H2 2015 75
Number of Products by Stage and Target, H2 2015 77
Number of Products by Stage and Mechanism of Action, H2 2015 81
Number of Products by Stage and Route of Administration, H2 2015 84
Number of Products by Stage and Molecule Type, H2 2015 86
Atherosclerosis Therapeutics - Recent Pipeline Updates, H2 2015 211
Atherosclerosis - Dormant Projects, H2 2015 238
Atherosclerosis - Dormant Projects (Contd..1), H2 2015 239
Atherosclerosis - Dormant Projects (Contd..2), H2 2015 240
Atherosclerosis - Dormant Projects (Contd..3), H2 2015 241
Atherosclerosis - Dormant Projects (Contd..4), H2 2015 242
Atherosclerosis - Discontinued Products, H2 2015 243
Atherosclerosis - Discontinued Products (Contd..1), H2 2015 244